{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-23-000109","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.194858+00:00","generated_at":"2026-06-11T21:24:41.330229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics Q2 net income $57.5M on royalty gain; $50M TZIELD milestone from Sanofi","bullets":["Net income of $57.5M ($0.92 diluted EPS) vs net loss of $41.3M a year ago; driven by $100.9M gain on royalty monetization.","Total revenue $13.1M, down from $26.0M YoY; collaborative revenue fell to $6.0M from $16.9M.","Cash $240.3M; plus $50M Sanofi milestone; cash runway extends into 2026.","Pipeline: TAMARACK Phase 2 for vobra duo in mCRPC enrolling under amended protocol; lorigerlimab Phase 2 to start.","Received $50M milestone from Sanofi after positive TZIELD Phase 3 data; additional $50M possible if net sales threshold met."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-23-000109","json":"https://secwatch.observer/filing/0001125345-23-000109.json","markdown":"https://secwatch.observer/filing/0001125345-23-000109.md","text":"https://secwatch.observer/filing/0001125345-23-000109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/0001125345-23-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/mgnx-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:24:41.330229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"342d46d77139f69070e1df3f374b93d00c110be1","claim":"MACROGENICS INC reported the quarter ended June 30, 2023 results: revenue $13.1 million.","evidence_excerpt":"Total revenue was $13.1 million for the quarter ended June 30, 2023, compared to total revenue of $26.0 million for the quarter ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/0001125345-23-000109-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$13.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}